BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23481536)

  • 1. Evaluating human papillomavirus vaccination programs.
    Donovan B; Guy RJ
    Sex Transm Dis; 2013 Apr; 40(4):290-1. PubMed ID: 23481536
    [No Abstract]   [Full Text] [Related]  

  • 2. Just implementation of human papillomavirus vaccination.
    Malmqvist E; Natunen K; Lehtinen M; Helgesson G
    J Med Ethics; 2012 Apr; 38(4):247-9. PubMed ID: 22138726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools].
    Dillner J; Andrae B; Westermark B
    Lakartidningen; 2006 Nov 1-7; 103(44):3377-9. PubMed ID: 17152260
    [No Abstract]   [Full Text] [Related]  

  • 4. Latin America. Price is the main barrier to wider use of papillomavirus vaccine.
    Kaiser J
    Science; 2008 May; 320(5878):860. PubMed ID: 18487164
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States.
    Castle PE; Solomon D; Saslow D; Schiffman M
    Cancer; 2008 Nov; 113(10 Suppl):3031-5. PubMed ID: 18980285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.
    Vanagas G; Padaiga Z
    Scand J Public Health; 2012 Jul; 40(5):406-11. PubMed ID: 22821227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of implementing human papillomavirus (HPV) vaccination policy.
    Raffle AE
    BMJ; 2007 Aug; 335(7616):375-7. PubMed ID: 17717366
    [No Abstract]   [Full Text] [Related]  

  • 8. Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?
    Porta M; González B; Márquez S; Artazcoz L
    J Epidemiol Community Health; 2008 Aug; 62(8):667. PubMed ID: 18621949
    [No Abstract]   [Full Text] [Related]  

  • 9. HPV vaccination in France: uptake, costs and issues for the National Health Insurance.
    Fagot JP; Boutrelle A; Ricordeau P; Weill A; Allemand H
    Vaccine; 2011 Apr; 29(19):3610-6. PubMed ID: 21382486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV vaccination.
    Brotherton J
    Aust Fam Physician; 2007 Jun; 36(6):391; author reply 391. PubMed ID: 17582901
    [No Abstract]   [Full Text] [Related]  

  • 11. Human papillomavirus vaccination: expected impacts and unresolved issues.
    Dempsey AF; Freed GL
    J Pediatr; 2008 Mar; 152(3):305-9. PubMed ID: 18280831
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.
    Khan K; Curtis CR; Ekwueme DU; Stokley S; Walker C; Roland K; Benard V; Saraiya M
    Cancer; 2008 Nov; 113(10 Suppl):3004-12. PubMed ID: 18980296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the coverage and impact of human papillomavirus vaccine - report of WHO meeting, November 2009.
    Wkly Epidemiol Rec; 2010 Jun; 85(25):237-43. PubMed ID: 20583384
    [No Abstract]   [Full Text] [Related]  

  • 14. Controlling cervical cancer.
    Bonati M; Garattini S
    Pharmacoeconomics; 2009; 27(2):91-3. PubMed ID: 19254043
    [No Abstract]   [Full Text] [Related]  

  • 15. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic impact of HPV vaccines: not just cervical cancer.
    Myers ER
    Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.
    Colantonio L; Gómez JA; Demarteau N; Standaert B; Pichón-Rivière A; Augustovski F
    Vaccine; 2009 Sep; 27(40):5519-29. PubMed ID: 19616499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccines: who will pay, who will receive, when to administer?
    Saslow D; Wheeler CM
    Ethn Dis; 2007; 17(2 Suppl 2):S2-8-13. PubMed ID: 17684807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global human papillomavirus vaccination: can it be cost-effective?
    Crosbie EJ
    BJOG; 2012 Jan; 119(2):125-8. PubMed ID: 22168760
    [No Abstract]   [Full Text] [Related]  

  • 20. Anticipating full benefits from the new papillomavirus vaccines.
    Griffiths PD
    Rev Med Virol; 2007; 17(1):1-3. PubMed ID: 17173349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.